Isocitrate dehydrogenase 1 (IDH1) and fibroblast growth factor receptor 2 (FGFR2), the two druggable genes, are frequently reported as therapeutic target gene abnormalities in intrahepatic cholangiocarcinoma (iCCA) [7]. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.